257 related articles for article (PubMed ID: 18676854)
1. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
Du X; Beers R; Fitzgerald DJ; Pastan I
Cancer Res; 2008 Aug; 68(15):6300-5. PubMed ID: 18676854
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
3. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
5. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
6. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
7. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
8. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
9. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
[TBL] [Abstract][Full Text] [Related]
10. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
Mansfield E; Pastan I; FitzGerald DJ
Bioconjug Chem; 1996; 7(5):557-63. PubMed ID: 8889017
[TBL] [Abstract][Full Text] [Related]
11. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
12. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
[TBL] [Abstract][Full Text] [Related]
13. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
17. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
Ho M; Kreitman RJ; Onda M; Pastan I
J Biol Chem; 2005 Jan; 280(1):607-17. PubMed ID: 15491997
[TBL] [Abstract][Full Text] [Related]
18. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
Bera TK; Onda M; Kreitman RJ; Pastan I
Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
[TBL] [Abstract][Full Text] [Related]
19. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
